INTRODUCTION

Veno-occlusive
disease/sinusoidal obstruction syndrome (VOD/SOS) of the liver is a serious complication of haematopoietic stem cell transplantation (HSCT). It is an early complication, usually due to endothelial injury as a result of toxicity of the conditioning treatment administered before HSCT. 1 The overall incidence of VOD/SOS in HSCT recipients is~14%, although it varies depending on the criteria used for diagnosis and the type of transplant performed, with incidences as high as 62% reported. 2 VOD/SOS is characterised by tender hepatomegaly, elevated serum bilirubin levels and weight gain. 1 Severe VOD/SOS is associated with a high mortality rate (84%), with most deaths resulting from multi-organ failure. 2 The introduction of new conditioning protocols and prophylaxis against VOD/SOS may have reduced the incidence in some centres. 3 However, one review suggested that the overall incidence has not decreased in recent years (and may even have increased), in part, as a result of more retransplantations and mismatched donors. 2 Defibrotide is the only drug approved in Europe and in the USA for the treatment of severe VOD/SOS following HSCT.
The British Committee for Standards in Haematology (BCSH) and the British Society for Blood and Marrow Transplantation (BSBMT) published recommendations for the diagnosis, prevention and management of VOD/SOS following HSCT in 2013. 4 The European Society for Blood and Marrow Transplantation (EBMT) published a position statement on VOD/SOS in 2015 and includes recommendations for prophylaxis and treatment in its handbook on HSCT. 5, 6 Our aim was to develop a consensus statement on the diagnosis, prevention and management of VOD/SOS in the Middle East and North Africa (MENA) region to help in the management of HSCT patients in the region.
METHODS
A group of regional experts in HSCT attended two face-to-face meetings to review the latest evidence on VOD/SOS, to discuss regional incidence of and risk factors for VOD/SOS and to develop a consensus on its diagnosis, prevention and management in the MENA region. They based their discussions on the BCSH/BSBMT guidelines, giving special consideration to issues of particular relevance in the region. 1 Table 1 summarises the consensus of the regional experts regarding the diagnosis, prevention and management of VOD/SOS in the MENA region.
RESULTS AND DISCUSSION
Regional incidence of VOD/SOS Regarding paediatric patients, the impression of the regional experts present at the meeting, taking into account data from King Faisal Specialist Hospital and Research Center, the largest regional centre, was that the incidence of VOD/SOS in the MENA region is around 10% in patients with thalassaemia (the most commonly seen patients), 15-20% in those with haemophagocytic lymphohistiocytosis, 60% in those with osteopetrosis (rarely seen) and 5% in children with haematological malignancies (with ALL being the most common). Adult patients undergoing HSCT usually have haematological malignancy, and the overall incidence of VOD/SOS is around 10%.
Diagnosis of VOD/SOS
The most commonly used criteria for diagnosing VOD/SOS are the Baltimore criteria and the modified Seattle criteria. The Baltimore criteria require a bilirubin level above 34.2 μmol/L (2 mg/dL) and two of hepatomegaly, ascites and weight gain of 45% from the pre-transplant weight. 7 The modified Seattle criteria require two of the following within 20 days of transplant: bilirubin 434.2 μmol/L, hepatomegaly or right upper quadrant pain and weight gain of 42% from pre-transplant weight. 8 The EBMT has recently produced new criteria for diagnosis of VOD/SOS. 9 According to these, patients fulfilling the Baltimore criteria within 21 days of transplant have classic VOD/SOS, whereas late-onset VOD/SOS comprises fulfilment of classic criteria after 21 days, histologically proven disease, or at least two of: bilirubin 42 mg/dL, hepatomegaly, weight gain 45%, ascites and haemodynamic and/or ultrasound evidence of VOD/SOS. 9 The MENA regional experts agreed that diagnosis of VOD/SOS should be based on established clinical criteria. VOD/SOS has different characteristics in children and adults, and diagnostic criteria for use in children are in development. 9 VOD/SOS is traditionally categorised as mild, moderate or severe, depending on adverse effects, requirement for treatment, duration of disease and mortality. 10 However, these categories can only be determined retrospectively and so are of limited clinical utility. Most patients with severe VOD/SOS develop multi-organ failure, so this can be considered a marker for the severity of the condition. 4 New EBMT criteria for severity grading of suspected VOD/SOS in adults grade disease as mild, moderate, severe or very severe (multi-organ dysfunction/failure) according to time since first clinical symptoms, bilirubin concentration, bilirubin kinetics, transaminases, weight increase and renal function (creatinine level and change from baseline). 9 VOD/SOS risk factors and their management A large number of risk factors for VOD/SOS have been identified. 4, 5, 10 One of the most important is pre-existing hepatic dysfunction, which may result from previous treatment (for example, abdominal irradiation or use of gemtuzumab ozogamicin), from viral hepatitis or from iron overload or liver fibrosis in patients with β-thalassaemia. Patients receiving allogeneic transplants are at greater risk than those receiving autologous transplants, as are those receiving a second or third transplant. Use of busulfan as a conditioning agent, especially in combination with cyclophosphamide, is associated with a higher incidence of VOD/SOS; the risk is lower when reduced-intensity conditioning regimens are used. The incidence is also higher in patients with an underlying diagnosis of osteopetrosis, primary haemophagocytic lymphohistiocytosis or adrenoleucodystrophy, as well as in those who have had previous abdominal radiography. Other patient-related risk factors include younger age in children, older age in adults and poor performance status. The experts agreed that patients should be assessed for risk factors for VOD/ SOS and that appropriate steps should be taken to address any modifiable risk factors before HSCT is undertaken.
The experts considered that iron overload and fibrosis in patients with haemoglobinopathies are important risk factors in the MENA region. They proposed that patients with a ferritin level below 1000 mg/dL and normal liver function tests can proceed to transplantation without further action. Those with ferritin levels between 1000 and 3000 mg/dL require further investigation; a biopsy may be needed to check for fibrosis, and VOD/SOS prophylaxis with defibrotide would be appropriate in patients receiving a transplant with these ferritin levels. In patients with ferritin levels above 3000 mg/dL, strong chelation is needed to reduce the ferritin level before a biopsy is done and transplantation goes ahead. Ideally, all patients with elevated ferritin would have a biopsy to check for fibrosis. However, this is not possible everywhere and non-invasive investigations, such as FibroScan may be used, with a FibroScan result of 7.7 kPa indicating severe fibrosis. The experts noted that it is not always possible to reduce ferritin to below 1000 mg/dL, so risk categorisation before transplantation should be applied. They agreed that T2*-weighted magnetic resonance imaging can indicate the degree of hepatic siderosis and will be useful in determining the need for VOD/SOS prophylaxis, with different criteria needed for haematology and oncology patients, and that patients with high-risk magnetic resonance imaging findings should receive prophylaxis.
Hepatitis B and C are important risk factors for VOD/SOS in the MENA region, and transplantation cannot be delayed for treatment of hepatitis in oncology patients. The consensus was that a biopsy should be considered in patients with antibodies and a positive PCR, and that those with chronic, active hepatitis B or C should receive VOD prophylaxis with defibrotide.
There was also a consensus that VOD/SOS prophylaxis with defibrotide is appropriate in patients with genetic/inherited conditions, such as osteopetrosis and various immunodeficiency, and metabolic disorders, such as haemophagocytic lymphohistiocytosis, in patients treated with gemtuzumab (or other similar monoclonal antibodies) and in those receiving a second transplantation (regardless of the indication). In general, the experts agreed that any patient with 10% or greater risk of developing VOD/SOS should receive prophylaxis with defibrotide.
Prophylaxis for VOD/SOS
An open-label, randomised controlled trial assessed prophylactic defibrotide in 356 paediatric patients who had undergone myeloablative conditioning before allogeneic or autologous HSCT and had at least one risk factor for VOD/SOS. 11 By 30 days post transplant, 12% of patients randomised to defibrotide had developed VOD/SOS compared with 20% of those who received placebo (P = 0.0488). No randomised controlled trial of prophylactic defibrotide has been conducted in adults, but two retrospective case series have reported promising results. 12, 13 The BCSH/BSBMT guideline recommends prophylaxis with defibrotide in children undergoing allogeneic HSCT with risk factors for VOD/SOS, and suggests defibrotide prophylaxis in adults. 4 The consensus among the MENA experts was that defibrotide should be used for VOD/SOS prophylaxis in patients with risk factors as discussed above. There is no evidence for using anything but the standard dose of 25 mg/kg per day, divided into four doses of 6.25 mg/kg. Prophylaxis should begin at the start of pre-transplant conditioning and should be continued until engraftment occurs.
A systematic review of four randomised studies of prophylactic ursodeoxycholic acid with or without additional treatment found a reduced risk of VOD/SOS compared with placebo, no treatment or the same additional treatment (risk ratio: 0.60, 95% confidence interval: 0.40-0.88).
14 No study of ursodeoxycholic acid versus defibrotide has been conducted. The regional experts concurred with the BCSH/BSBMT guideline in suggesting ursodeoxycholic acid for use in the prophylaxis of VOD/SOS. A case can be made for using it in all patients and adding defibrotide in those at increased risk. Prostaglandin E1, pentoxifylline, heparin and antithrombin are not recommended for prophylaxis.
Treatment of VOD/SOS The BCSH/BSBMT guideline recommends defibrotide for the treatment of VOD/SOS in adults and children. 4 Following a pilot study of compassionate use of defibrotide in 19 patients with severe VOD, 15 which reported a 42% resolution rate, another 69 patients were studied prospectively. The complete response (CR) rate (bilirubin o 34.2 μmol/L and improvement of other symptoms and signs of VOD) in the 88 patients was 36%, with 35% survival at day 100. 16 A Phase 2 randomised dose-finding study in 149 patients found a CR rate of 46%, with no difference in efficacy between doses but a slightly higher adverse event rate for 40 versus 25 mg/kg per day. 17 In a Phase 3 study, 102 patients meeting the Baltimore criteria for VOD/SOS with additional criteria for severe VOD were treated with defibrotide 6.25 mg/kg four times daily and were compared with 32 historical controls. CR (bilirubin o34.2 μmol/L and resolution of multi-organ failure) at day 100 was 26% compared with 13% for controls (P = 0.016), whereas mortality was 62% for treated patients and 75% for controls (P = 0.011). 18 The latest data from an expanded access programme in the US show 100-day survival rates of 58% in 283 paediatric patients and 45% for 243 adult patients. 19 Higher survival rates in patients with nonsevere VOD/SOS (67% for paediatric and 52% for adults) suggest that further study may be warranted to determine the impact of treatment earlier in the disease course. 20 Data from an international compassionate use programme in 710 patients show a 100-day survival rate of 58% for patients receiving the recommended dose of 25 mg/kg per day. 21 A prospective study of intravenous methylprednisolone 0.5 mg/kg twice daily in 48 patients with VOD/SOS (31% with multi-organ failure) reported a response rate (⩾50% decrease in bilirubin within 10 days) of 63% and a 100-day survival rate of 58%. 22 More recently, in a retrospective study of IV methylprednisolone 500 mg/m 2 every 12 h for six doses (followed by a taper to 2 mg/kg per day for 3 days, and subsequently tapered per treating physician preference) in nine paediatric patients (eight with multi-organ failure), six patients responded and the survival rate was 78%. 23 The BCSH/BSBMT guideline states that methylprednisolone may be considered for use in the treatment of VOD/SOS with the appropriate caveats of caution regarding infection. 4 Tissue plasminogen activator and N-acetylcysteine are not recommended for the treatment of VOD/SOS.
The MENA consensus was that defibrotide at the recommended dose of 25 mg/kg per day should be used to treat HSCT patients with severe or very severe VOD/SOS according to the new EBMT severity criteria. Patients with moderate VOD/SOS can also receive treatment if it is clinically indicated in the judgement of the treating physician. For example, a patient with moderate disease and one risk factor (as detailed above) may be considered a candidate for treatment. Treatment should be continued until resolution of symptoms, or for a minimum of 21 days. Uncontrolled bleeding would be a reason to stop defibrotide treatment early, but this is a very rare occurrence. Methylprednisolone is an acceptable alternative if defibrotide cannot be used. All patients should receive appropriate supportive care, particularly management of fluid balance.
